OrbusNeich Says “Bio-Engineered” Stent May Be Solution To Thrombosis Risk
This article was originally published in The Gray Sheet
Executive Summary
OrbusNeich hopes to lead a new wave of stent technology with its Genous Bio-engineered R-Stent, which the firm says is safer than existing drug-eluting stents because it has a natural antibody coating instead of a drug-eluting polymer
You may also be interested in...
New Stents On The Block: Innovators Look Beyond Drug Coatings
Several small start-ups are vying to steal the spotlight from the major coronary stent makers with novel stent designs and surface coatings that have clinicians taking note
New Stents On The Block: Innovators Look Beyond Drug Coatings
Inventors are taking a second look at bare-metal stents, which may be better suited for certain vessels or lesions, and could be mixed and matched with drug-eluting stents for optimum results.
New Stents On The Block: Innovators Look Beyond Drug Coatings
Several small start-ups are vying to steal the spotlight from the major coronary stent makers with novel stent designs and surface coatings that have clinicians taking note